Imai, K.; Takai, K.; Unome, S.; Miwa, T.; Hanai, T.; Suetsugu, A.; Shimizu, M.
Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates. Cancers 2023, 15, 4223.
https://doi.org/10.3390/cancers15174223
AMA Style
Imai K, Takai K, Unome S, Miwa T, Hanai T, Suetsugu A, Shimizu M.
Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates. Cancers. 2023; 15(17):4223.
https://doi.org/10.3390/cancers15174223
Chicago/Turabian Style
Imai, Kenji, Koji Takai, Shinji Unome, Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, and Masahito Shimizu.
2023. "Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates" Cancers 15, no. 17: 4223.
https://doi.org/10.3390/cancers15174223
APA Style
Imai, K., Takai, K., Unome, S., Miwa, T., Hanai, T., Suetsugu, A., & Shimizu, M.
(2023). Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates. Cancers, 15(17), 4223.
https://doi.org/10.3390/cancers15174223